Suggested remit: To appraise the clinical and cost effectiveness of mavacamten within its marketing authorisation for treating symptomatic obstructive hypertrophic cardiomyopathy
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3928

Provisional Schedule

Committee meeting 06 December 2022
Expected publication 01 March 2023

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Bristol-Myers Squibb (mavacamten)
Others Department for Health and Social Care
  NHS England
  NHS Newcastle Gateshead CCG
  NHS Sutton CCG
  Welsh Government
Patient carer groups Arrythmia Alliance
  Atrial Fibrillation Association
  Blood Pressure UK
  British Cardiac Patients Association
  Cardiac Risk in the Young
  Cardiomyopathy UK
  Cardiovascular Care Partnership
  Circulation Foundation
  Genetic Alliance
  HEART UK
  Network of Sikh Organisations
  Pumping Marvellous Foundation
  Somerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Genetic Nurses and Counsellors
  British Association for Nursing in Cardiovascular Care
  British Atherosclerosis Society
  British Cardiovascular Intervention Society
  British Cardiovascular Society
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Nuclear Cardiology Society
  British Society for Cardiovascular Research
  British Society of Echocardiography
  British Society for Gene and Cell Therapy
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Heart Failure
  British Society for Human Genetics
  British Society of Cardiovascular Imaging
  National Heart and Lung Institute
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiological Science and Technology
  Society for Vascular Nurses
  Society for Vascular Technology
  UK Clinical Pharmacy Association
  UK Genetic Testing Network
  Vascular Society of Great Britain and Ireland
Associated public health groups UK Health Security Agency
  Public Health Wales
Comparator companies Accord (atenolol, bisoprolol, metoprolol, , propranolol, verapamil)
  AstraZeneca (atenolol,)
  Aurobindo Pharma (bisoprolol, metoprolol, propranolol,)
  Cheplapharma Arzneimittel (disopyramide)
  Chiesi (verapamil)
  Dexcel Pharma (verapamil)
  Ethypharm (diltiazem)
  Flamingo Pharma (bisoprolol)
  Galen (diltiazem)
  Kent Pharma (diltiazem)
  Merck (bisoprolol, diltiazem)
  Mylan (disopyramide, diltiazem, verapamil)
  Napp Pharmaceuticals (diltiazem)
  Recordati Pharmaceuticals (metoprolol)
  Rosemont Pharmaceuticals (propranolol, verapamil)
  Sandoz (bisoprolol)
  Sanofi (diltiazem)
  Sigma Pharmaceuticals (atenolol)
  Thame Laboratories (atenolol, propranolol)
  Thornton & Ross (diltiazem)
  Tillomed Laboratories (propranolol, verapamil)
  Wockhardt UK (atenolol)
  Zentiva (diltiazem)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Cell and Gene Therapy Catapult
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Dept, Barts
  Cochrane Heart Group
  Cochrane Vascular
  European Council for Cardiovascular Research
  Heart Research UK
  MRC Clinical Trials Unit
  National Centre for Cardiovascular Prevention and Outcomes
  National Institute for Health Research
  Society for Research in Rehabilitation
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
29 April 2022 Following on from advice received from the company the timelines for this appraisal have been amended. Therefore, the committee meeting on 04 October 2022 has been rescheduled to take place on 6 December 2022.
04 February 2022 Invitation to participate
04 February 2022 In progress. ITP issued
03 September 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2022 when we will write to consultees and commentators about how they can get involved.
20 August 2021 (14:00) Scoping workshop
02 July 2021 - 30 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual